ImmuPharma PLC Net Assets

Latest as of June 2025: GBX336.70K GBX ≈ $40.97 USD

ImmuPharma PLC net assets. Based on the latest financial reports, ImmuPharma PLC (IMM) has net assets worth GBX336.70K GBX (≈ $40.97 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.58 Million ≈ $192.34 USD) and total liabilities (GBX1.24 Million ≈ $151.37 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMM shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX336.70K
% of Total Assets 21.3%
Annual Growth Rate N/A
5-Year Change -105.62%
10-Year Change -132.11%
Growth Volatility 102.98

Net Assets of ImmuPharma PLC (2004–2024)

Net assets of ImmuPharma PLC from 2004 to 2024. This chart illustrates how ImmuPharma PLC's net assets have evolved over time, based on quarterly financial data. See ImmuPharma PLC net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for ImmuPharma PLC (2004–2024)

The table below shows the annual net assets of ImmuPharma PLC from 2004 to 2024. For live market cap and overall valuation, see IMM market cap.

Year Net Assets Change
2024-12-31 GBX-542.86K
≈ $-66.05		 -151.39%
2023-12-31 GBX1.06 Million
≈ $128.52		 -58.14%
2022-12-31 GBX2.52 Million
≈ $307.02		 -42.83%
2021-12-31 GBX4.41 Million
≈ $536.99		 -54.29%
2020-12-31 GBX9.65 Million
≈ $1.17K		 +83.23%
2019-12-31 GBX5.27 Million
≈ $641.11		 -30.88%
2018-12-31 GBX7.62 Million
≈ $927.50		 +113.26%
2017-12-31 GBX3.57 Million
≈ $434.91		 -35.55%
2016-12-31 GBX5.55 Million
≈ $674.79		 +228.09%
2015-12-31 GBX1.69 Million
≈ $205.67		 -70.37%
2014-12-31 GBX5.71 Million
≈ $694.18		 +5.58%
2013-12-31 GBX5.40 Million
≈ $657.48		 -35.81%
2012-12-31 GBX8.42 Million
≈ $1.02K		 -32.69%
2011-12-31 GBX12.51 Million
≈ $1.52K		 -21.69%
2010-12-31 GBX15.97 Million
≈ $1.94K		 -11.69%
2009-12-31 GBX18.08 Million
≈ $2.20K		 +60.88%
2008-12-31 GBX11.24 Million
≈ $1.37K		 +268.52%
2007-12-31 GBX3.05 Million
≈ $371.10		 -48.18%
2006-12-31 GBX5.89 Million
≈ $716.16		 +135.06%
2006-03-31 GBX2.50 Million
≈ $304.66		 +152.17%
2005-03-31 GBX993.00K
≈ $120.82		 +1.53%
2004-03-31 GBX978.00K
≈ $118.99		 --

Equity Component Analysis

This analysis shows how different components contribute to ImmuPharma PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6591214.3% over the analyzed period, potentially due to dividend distributions or operating losses.

ImmuPharma PLC Net Assets Breakdown (December 2024)

ImmuPharma PLC net assets breakdown by equity component as of December 2024.

Component Amount Percentage
Common Stock GBX29.81 Million %
Other Components GBX35.56 Million %
Total Equity GBX-542.86K 100.00%

ImmuPharma PLC Competitors by Market Cap

The table below lists competitors of ImmuPharma PLC ranked by their market capitalization.

Company Market Cap
Empresaria Group plc
LSE:EMR
 $202.92K
Global PVQ SE
HM:QCE
 $206.16K
TEVANO SYSTEMS HLDGS INC.
F:7RBA
 $210.67K
Aquila Energy Efficiency Trust PLC
LSE:AEET
 $213.04K
Premier Health of America Inc
V:PHA
 $200.79K
Realfiction Holding AB
ST:REALFI
 $200.53K
Tan Delta Systems PLC
LSE:TAND
 $200.46K
CARLYLE COMMODIT.CORP.
F:BJ4
 $199.86K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ImmuPharma PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,056,289 to -542,859, a change of -1,599,148 (-151.4%).
  • Net loss of 2,483,000 reduced equity.
  • Other comprehensive income decreased equity by 6,008,738.
  • Other factors increased equity by 6,892,590.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX-2.48 Million -457.39%
Other Comprehensive Income GBX-6.01 Million -1106.87%
Other Changes GBX6.89 Million +1269.68%
Total Change GBX- -151.39%

Book Value vs Market Value Analysis

This analysis compares ImmuPharma PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-03-31 GBX0.23 GBX3.29 x
2005-03-31 GBX0.24 GBX3.29 x
2006-03-31 GBX0.04 GBX3.29 x
2006-12-31 GBX0.08 GBX3.29 x
2007-12-31 GBX0.04 GBX3.29 x
2008-12-31 GBX0.14 GBX3.29 x
2009-12-31 GBX0.22 GBX3.29 x
2010-12-31 GBX0.20 GBX3.29 x
2011-12-31 GBX0.15 GBX3.29 x
2012-12-31 GBX0.10 GBX3.29 x
2013-12-31 GBX0.07 GBX3.29 x
2014-12-31 GBX0.07 GBX3.29 x
2015-12-31 GBX0.02 GBX3.29 x
2016-12-31 GBX0.05 GBX3.29 x
2017-12-31 GBX0.03 GBX3.29 x
2018-12-31 GBX0.05 GBX3.29 x
2019-12-31 GBX0.03 GBX3.29 x
2020-12-31 GBX0.05 GBX3.29 x
2021-12-31 GBX0.02 GBX3.29 x
2022-12-31 GBX0.01 GBX3.29 x
2023-12-31 GBX0.00 GBX3.29 x
2024-12-31 GBX0.00 GBX3.29 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ImmuPharma PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-79.68%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 0.10% 0.00% 0.00x 1.00x GBX-96.80K
2005 1.51% 0.00% 0.00x 1.01x GBX-84.30K
2006 -99.16% -9932.00% 0.01x 1.45x GBX-2.73 Million
2006 -42.13% -4150.22% 0.01x 1.24x GBX-3.07 Million
2007 -101.08% -4893.65% 0.02x 1.34x GBX-3.39 Million
2008 41.61% 8205.26% 0.00x 1.19x GBX3.55 Million
2009 44.81% 36.74% 0.89x 1.36x GBX6.29 Million
2010 -12.39% -6181.25% 0.00x 1.10x GBX-3.58 Million
2011 -26.83% -19735.29% 0.00x 1.14x GBX-4.61 Million
2012 -45.66% 0.00% 0.00x 1.25x GBX-4.69 Million
2013 -68.27% 0.00% 0.00x 1.33x GBX-4.23 Million
2014 -50.32% -1553.45% 0.03x 1.24x GBX-3.44 Million
2015 -230.54% -5100.32% 0.02x 1.90x GBX-4.07 Million
2016 -96.00% -3230.90% 0.02x 1.21x GBX-5.88 Million
2017 -174.09% -4135.93% 0.03x 1.40x GBX-6.58 Million
2018 -94.54% -8866.77% 0.01x 1.14x GBX-7.97 Million
2019 -116.22% -7858.84% 0.01x 1.10x GBX-6.65 Million
2020 -71.05% -5415.78% 0.01x 1.13x GBX-7.83 Million
2021 -185.20% -6906.63% 0.02x 1.36x GBX-8.62 Million
2022 -150.87% 0.00% 0.00x 1.58x GBX-4.06 Million
2023 -276.63% 0.00% 0.00x 2.58x GBX-3.03 Million
2024 0.00% 0.00% 0.00x 0.00x GBX-2.43 Million

Industry Comparison

This section compares ImmuPharma PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $7,477,166
  • Average return on equity (ROE) among peers: -144.82%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ImmuPharma PLC (IMM) GBX336.70K 0.10% 3.69x $201.24K
4BASEBIO UK SOCIETAS (4BB) $11.70 Million -27.66% 0.26x $998.55K
Aptamer Group PLC (APTA) $245.81K -274.50% 4.65x $93.52K
Arecor Therapeutics PLC (AREC) $5.35 Million -191.36% 0.63x $356.03K
Avacta Group PLC (AVCT) $19.13 Million -52.99% 0.12x $2.86 Million
BSF Enterprise Plc (BSFA) $423.14K -22.20% 0.08x $15.62K
Bioventix (BVXP) $851.00K 0.00% 1.80x $1.24 Million
Cizzle Biotechnology Holdings PLC (CIZ) $2.40 Million -115.05% 1.12x $55.46K
CRISM Therapeutics Corporation (CRTX) $23.48 Million -13.39% 0.12x $81.89K
Fusion Antibodies PLC (FAB) $16.32K -695.70% 18.23x $72.60K
Faron Pharmaceuticals Oy (FARN) $11.18 Million -55.36% 0.33x $401.90K

About ImmuPharma PLC

LSE:IMM UK Biotechnology
Market Cap
$201.24K
GBX1.65 Billion GBX
Market Cap Rank
#31352 Global
#1016 in UK
Share Price
GBX3.29
Change (1 day)
+9.48%
52-Week Range
GBX3.01 - GBX10.70
All Time High
GBX190.00
Categories
Companies in UK Biotechnology
About

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more